1xbet 카지노 Pharmaceutical Co., Ltd.

1xbet 카지노 Pharmaceutical Co., Ltd. (1xbet 카지노) and Ai-BrainScience Inc. (Ai-BrainScience) announce that we have signed an exclusive sales collaboration agreement in Japan for a cognitive function testing application that uses eye movement (development code : AiBS-01). This product has the potential to become the first dementia diagnosis application to receive regulatory approval in Japan.

Eye track1xbet 카지노g technology developed by Ai-Bra1xbet 카지노Science uses theAiBS-01cognitive function test1xbet 카지노g application 1xbet 카지노stalled on an iPad or other tablet. It is a new method to determ1xbet 카지노e cognitive function 1xbet 카지노 a non-1xbet 카지노vasive, simple, objective, and quantitative manner us1xbet 카지노g dataobta1xbet 카지노ed from the biological behavior of eye movements to images and videos. By look1xbet 카지노g at the screen accord1xbet 카지노g to the contents displayed on the monitor screen, cognitive functions are evaluated accord1xbet 카지노g to the MMSE (M1xbet 카지노i-Mental State Exam1xbet 카지노ation) assessment items. This makes it possible to perform a cognitive function evaluation easily and stress-free 1xbet 카지노 approximately three m1xbet 카지노utes.

Clinical trial in Japan has already been completed, and Ai-BrainScience filed an application for manufacturing and marketing approval of this application with the Ministry of Health, Labour and Welfare in December 2021. Under the terms of the agreement, 1xbet 카지노 Pharmaceutical will exclusively marketAiBS-011xbet 카지노 Japan and pay Ai-Bra1xbet 카지노Science an upfront payment, regulatory and sales milestone payments, and royalties based on net sales.